Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
PCYC [NASD]
Pharmacyclics Inc.
Index- P/E238.38 EPS (ttm)1.08 Insider Own18.30% Shs Outstand76.79M Perf Week-0.35%
Market Cap19.77B Forward P/E59.25 EPS next Y4.35 Insider Trans-0.70% Shs Float61.90M Perf Month0.01%
Income86.10M PEG1489.87 EPS next Q0.12 Inst Own78.40% Short Float3.71% Perf Quarter79.72%
Sales729.70M P/S27.09 EPS this Y26.40% Inst Trans0.03% Short Ratio1.44 Perf Half Y138.31%
Book/sh10.95 P/B23.51 EPS next Y770.74% ROA9.60% Target Price243.34 Perf Year185.93%
Cash/sh11.16 P/C23.07 EPS next 5Y0.16% ROE12.00% 52W Range82.51 - 260.47 Perf YTD110.58%
Dividend- P/FCF123.10 EPS past 5Y40.90% ROI10.40% 52W High-1.16% Beta0.67
Dividend %- Quick Ratio5.10 Sales past 5Y139.30% Gross Margin94.50% 52W Low212.02% ATR1.63
Employees607 Current Ratio5.20 Sales Q/Q134.80% Oper. Margin47.70% RSI (14)76.98 Volatility0.78% 0.63%
OptionableYes Debt/Eq0.00 EPS Q/Q-1.20% Profit Margin11.80% Rel Volume1.95 Prev Close258.02
ShortableYes LT Debt/Eq0.00 EarningsApr 30 BMO Payout0.00% Avg Volume1.59M Price257.45
Recom2.70 SMA200.10% SMA5013.02% SMA20071.18% Volume3,096,156 Change-0.22%
Mar-06-15Reiterated WallachBeth Hold $222 → $261
Mar-05-15Reiterated RBC Capital Mkts Sector Perform $145 → $261
Feb-26-15Downgrade WallachBeth Buy → Hold $228
Feb-19-15Reiterated Deutsche Bank Buy $180 → $205
Feb-19-15Downgrade ROTH Capital Buy → Neutral $189 → $187
Jan-29-15Reiterated ROTH Capital Buy $188 → $189
Oct-17-14Reiterated ROTH Capital Buy $185 → $188
Oct-14-14Reiterated ROTH Capital Buy $183 → $185
Aug-01-14Upgrade WallachBeth Hold → Buy
May-27-14Downgrade RBC Capital Mkts Outperform → Sector Perform $110 → $95
May-05-14Reiterated RBC Capital Mkts Outperform $150 → $110
Feb-21-14Reiterated Deutsche Bank Buy $170 → $180
Dec-18-13Initiated WallachBeth Hold $108
Sep-26-13Initiated Deutsche Bank Buy $170
Dec-12-12Reiterated Wedbush Outperform $93 → $110
Aug-24-12Initiated Stifel Nicolaus Hold
Aug-02-12Downgrade Needham Buy → Hold
May-17-12Reiterated Rodman & Renshaw Mkt Outperform $22 → $40
May-17-12Reiterated Needham Buy $23 → $32
Feb-21-12Upgrade RBC Capital Mkts Sector Perform → Outperform $15 → $34
Apr-17-15 05:07PM  AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. at noodls
Apr-16-15 01:47PM  Basics of the Informatica Merger
01:45PM  The Informatica Merger Spread Currently Yields About 4%
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Pharmacyclics, Geron, Anthera Pharmaceuticals and Cytori Therapeutics - Press Releases
Apr-15-15 10:52AM  3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
12:03AM  [$$] J&Js Profit Falls on Strong Dollar, Weak Medical-Device Sales at The Wall Street Journal
Apr-14-15 05:48PM  J&J Earnings Beat Estimates; Guidance Mixed at Investor's Business Daily
11:12AM  J&J Earnings Beat Estimates; Guidance Mixed at Investor's Business Daily
08:37AM  Johnson & Johnson (JNJ) Stock Climbing Today on Better Than Expected First Quarter Earnings at TheStreet
08:24AM  J&J's Profits Fall as Dollar Rises at The Wall Street Journal
Apr-13-15 03:58PM  What to watch for in Johnson & Johnson earnings at MarketWatch
03:17PM  What to Expect When Johnson & Johnson (JNJ) Reports First-Quarter Earnings Tomorrow at TheStreet
12:00PM  What to expect from Johnson & Johnson earnings at MarketWatch
11:19AM  AbbVie Upgraded On $7.8 Billion Imbruvica Potential at Investor's Business Daily
10:46AM  One Analyst Changes His Tune on AbbVie and its Pharmacyclics Deal at The Wall Street Journal
Apr-09-15 10:50AM  Mylan Proposes to Acquire Perrigo, Sets Both Stocks Soaring - Analyst Blog
09:00AM  New Longer-Term IMBRUVICA® (ibrutinib) Data Show High Response Rates in Patients with Waldenstrom's Macroglobulinemia PR Newswire
Apr-07-15 12:58PM  AbbVie Inc. -- Moody's confirms AbbVie's Baa1 ratings; outlook negative at Moody's
Apr-06-15 10:26PM  3 Long-Tail Growth Drivers for Johnson & Johnson at Investopedia
Apr-03-15 10:44PM  A Winning Quarter for Active Managers at Barrons.com
Apr-02-15 11:54AM  Pharmacyclics, Inc. (PCYC), Horizon Pharma PLC (HZNP), Auspex Pharmaceuticals Inc (ASPX): Hedge Funds Cashing In On Highest Q1 Gainers at Insider Monkey
09:50AM  Pharmacyclics Begins Imbruvica Combination Cancer Study - Analyst Blog
Apr-01-15 09:00AM  Solid Tumor Study Investigating Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic Cancers PR Newswire
06:01AM  Soaring biotech stocks are looking a bit sickly at MarketWatch
01:00AM  Pharma's Comeback Deals Keep Drug M&A on Track to Reach Records
12:19AM  [$$] Vital Signs Show Market for Health-Care Deals In the Pink at The Wall Street Journal
Mar-31-15 06:09PM  Market for Health Deals Is In the Pink at The Wall Street Journal
09:54AM  What I Hope Everyone Learns From PBS' Big Cancer Documentary at Forbes
Mar-30-15 09:06AM  Is the PharmacyclicsAbbVie Merger a Setup?
Mar-28-15 01:05AM  The Risk-to-Reward Ratio of the PharmacyclicsAbbVie Merger
01:05AM  The PharmacyclicsAbbVie Merger: What Are the Details?
Mar-27-15 07:23PM  Cramer Remix: A bottom in biotech? Hardly at CNBC
06:40PM  Cramer: 4 horsemen of biotech & semis are back at CNBC
06:25PM  Four horsemen of semis & biotech: Cramer
Mar-26-15 06:06PM  Transaction Basics of the Life Time Fitness Merger
03:58PM  New ETF From BlackRock And Edelman
Mar-25-15 04:57PM  Merger momentum keeps on rolling with Heinz deal for Kraft
03:56PM  Heinz $46 Billion Kraft Bid Is a Megadeal Without Megabanks
11:10AM  4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
10:06AM  The PharmacyclicsAbbVie Merger: The Basics of Pharmacyclics
Mar-24-15 03:55PM  Morningstar, iShares and Ric Edelman say these are the most innovative stocks at MarketWatch
12:06PM  Could the PharmacyclicsAbbVie Merger Get Competitive?
11:57AM  Edelman, iShares Launch Exponential Technologies ETF ETF Trends
11:57AM  Edeleman, iShares Launch Exponential Technologies ETF ETF Trends
09:00AM  TG Therapeutics Is A Best Idea at Forbes
Mar-23-15 02:05PM  Is Antitrust a Risk in the PharmacyclicsAbbVie Merger?
01:31PM  Pharmacyclics chief to receive $3.6bn from takeover at Financial Times
10:06AM  Rationale for the PharmacyclicsAbbVie Merger
08:22AM  PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Mar-20-15 11:58AM  The PharmacyclicsAbbVie Merger Shareholders Could Benefit
Mar-19-15 10:42PM  Big Pharma Needs to Get Busy in the Lab at The Wall Street Journal
06:52PM  Big Pharma Needs to Get Busy in the Lab at The Wall Street Journal
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releases
09:00AM  New ibrutinib (IMBRUVICA®) Data to be Presented at American Association for Cancer Research (AACR) Meeting PR Newswire
Mar-18-15 07:34PM  Cramer Remix: Oil news you've been waiting for at CNBC
01:27PM  PHARMACYCLICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
10:49AM  Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog
Mar-17-15 04:20PM  Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog
02:41PM  AbbVie to Buy Pharmacyclics: Biotech ETFs to Watch - ETF News And Commentary
06:05AM  Jim Cramer on Biotech Stocks the Market Always Seems to Undervalue at TheStreet
06:02AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-16-15 06:17PM  Cramer: This sector has tons of hidden opportunity at CNBC
06:00PM  Cramer: Skepticism too thick
05:08PM  Pharmacyclics cancer drug successful as combination therapy - independent panel Reuters
04:25PM  Why the Bull Isn't Done Running - Video Blog
03:42PM  FDA panel recommends unblinding study after Imbruvica shows clear benefit Reuters
03:00PM  Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA® (ibrutinib) Phase III Combination HELIOS Trial Based on Interim Analysis Showing Significant Improvement in Progression-Free Survival in Patients with Chr PR Newswire
11:00AM  Valeant Pharmaceuticals Poised To Win Bidding War For Salix With $173 A Share Cash Deal at Forbes
Mar-12-15 05:20PM  Salix Up on Endo Proposal Outstripping Valeant Offer - Analyst Blog
09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Pharmacyclics, Amgen, United Therapeutics and Regeneron - Press Releases
Mar-11-15 06:01PM  Endo offers about $11 bln for Salix, trumping Valeant Reuters
02:02PM  Endo Intl has offered to buy Salix Pharma -source
09:54AM  Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog
Mar-10-15 11:17AM  Pharmacyclics Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover PR Newswire
11:00AM  ETFs for the Next Biotech Takeover Targets ETF Trends
10:52AM  Prescription drug spending on the rise
Mar-09-15 07:00PM  Drugmaker Galapagos Evolves Into Target for AbbVie, J&J at Bloomberg
02:34PM  Three Reasons to Fear Biotech Stocks Right Now at Barrons.com
12:45PM  PHARMACYCLICS INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to AbbVie Business Wire
11:21AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Pharmacyclics Inc. of Commencement of Class Action Investigation Concerning the Fairness of the Sale of the Company to AbbVie Business Wire
10:55AM  Ryan & Maniskas, LLP Announces Investigation of Pharmacyclics Inc. PR Newswire
09:30AM  A Biotech ETF Right for Oncology Mergers and Acquisitions ETF Trends
Mar-06-15 06:56PM  SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Pharmacyclics, Inc. - PCYC PR Newswire
04:21PM  Pharmacyclics Set to Be Acquired by AbbVie for $21B - Analyst Blog Zacks
02:12PM  Going the extra mile to win a £21bn deal at Financial Times
01:51PM  AbbVie: Pharmacyclics Acquisition 'Deals a Huge Blow' to Bears at Barrons.com
11:28AM  AbbVie joins the pharma chain reaction at Financial Times
11:28AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of PHARMACYCLICS INC. of Commencement of Class Action Investigation Concerning the Fairness of the SALE OF THE COMPANY TO ABBVIE -- PCYC PR Newswire
08:45AM  Credit Suisse Reiterates Neutral, Raises PT On Pharmacyclics As Deal Looks Likely To Happen Benzinga
08:20AM  The Next 3 Likely Biotech Buyout Candidates at 24/7 Wall St.
07:54AM  Bubble trouble in biotech? CNBC
07:04AM  The Morning Ledger: Why CFOs Should Look Past Numbers to Evaluate a Deal at The Wall Street Journal
12:34AM  Biotech Bidding War Yields Rich Price at The Wall Street Journal
12:27AM  AbbVies Expensive Growth Tonic at The Wall Street Journal
Mar-05-15 08:25PM  Bidding War Yields Rich Price for Biotech at The Wall Street Journal +10.30%
08:00PM  Harwood Feffer LLP Announces Investigation of Pharmacyclics, Inc. PR Newswire
07:25PM  Biz Break: Pharmacyclics cofounder on $21B buyout -- 'This is a company that kept fighting' at San Jose Mercury News
06:57PM  Bored by Golf and Cancer Cured, AbbVie CEO Came Back to Work Bloomberg
06:55PM  Billionaire Robert Duggan's Bet On Pharmacyclics Stands Among Top Trades Of Crisis Era at Forbes
06:42PM  Bored by Golf and Cured of Cancer, AbbVie CEO Came Back for More at Bloomberg
Pharmacyclics, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a first-in-class, oral, once-daily, single-agent therapy used for the treatment of patients with: chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17; mantle cell lymphoma who have received at least one prior therapy; and all lines of waldenstrm's macroglobulinemia (WM). Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under phase I, II, III clinical trials for the treatment of CCL, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, WM, marginal zone lymphoma, graft versus host disease, acute lymphoblastic leukemia, acute myeloid leukemia, and solid tumors and others. The company's product candidates also comprise BTK Inhibitor Program that is in pre-clinical testing, phase I for the treatment of autoimmune; Abexinostat HDAC Inhibitor, which is in phase I and II clinical trials for treating relapsed/refractory lymphomas and solid tumors; and Factor VIIa Inhibitor, which is in phase II complete/program under review for the treatment of cancer. Pharmacyclics, Inc. has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize IMBRUVICA and certain compounds for oncology and other indications. The company was founded in 1991 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tan HeowChief Quality&Tech OperationsMar 17Option Exercise27.053,69699,9777,766Mar 17 08:05 PM
Soni Manmeet SinghChief Financial OfficerMar 13Sale254.913,416870,75654,611Mar 13 06:25 PM
Zanganeh MakyChief Operating OfficerMar 12Option Exercise0.7592,50069,375317,812Mar 13 05:54 PM
Tan HeowChief Quality&Tech OperationsMar 12Option Exercise27.051,00027,0505,070Mar 12 07:24 PM
Tan HeowChief Quality&Tech OperationsMar 12Sale254.511,000254,5064,070Mar 12 07:24 PM
Soni Manmeet SinghChief Financial OfficerMar 11Option Exercise75.0624,0981,808,84982,125Mar 13 06:25 PM
Zanganeh MakyChief Operating OfficerMar 11Option Exercise7.1930,000215,700255,312Mar 13 05:54 PM
Zanganeh MakyChief Operating OfficerMar 11Sale254.1130,0007,623,444225,312Mar 13 05:54 PM
Soni Manmeet SinghChief Financial OfficerMar 11Sale254.1524,0986,124,50758,027Mar 13 06:25 PM
Soni Manmeet SinghChief Financial OfficerNov 13Option Exercise61.601,00061,60039,611Nov 17 04:19 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Option Exercise6.843,00020,5206,193Nov 17 04:30 PM
Soni Manmeet SinghChief Financial OfficerNov 13Sale141.441,000141,44238,611Nov 17 04:19 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Sale141.303,000423,9023,193Nov 17 04:30 PM
Zanganeh MakyChief Operating OfficerNov 12Option Exercise7.195,93142,644216,243Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 12Sale137.965,931818,216210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Option Exercise32.381,50048,5701,705Nov 10 06:30 PM
Zanganeh MakyChief Operating OfficerNov 10Option Exercise2.3023,00052,900233,312Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 10Sale133.8323,0003,078,027210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Sale133.871,500200,805205Nov 10 06:30 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Option Exercise6.845,00034,2008,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerNov 07Option Exercise2.301,5513,567211,863Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 07Sale135.011,551209,401210,312Nov 12 06:07 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Sale134.505,000672,5003,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerSep 04Option Exercise2.305,00011,500215,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 04Sale122.005,000610,000210,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Option Exercise2.307,00016,100217,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Sale121.577,000850,980210,311Sep 04 05:54 PM
Love Richard BGeneral CounselAug 27Option Exercise32.381,50048,5701,704Aug 28 09:52 PM
Love Richard BGeneral CounselAug 27Sale124.001,500186,000204Aug 28 09:52 PM
Tan HeowChief Quality&Tech OperationsAug 21Option Exercise27.052,19659,4024,069Aug 22 02:45 PM
Tan HeowChief Quality&Tech OperationsAug 13Option Exercise27.0510,000270,50011,873Aug 13 05:27 PM
Tan HeowChief Quality&Tech OperationsAug 13Sale123.5810,0001,235,8081,873Aug 13 05:27 PM
McGreivy JesseChief Medical OfficerAug 07Option Exercise73.0934,0622,489,51534,062Aug 07 06:51 PM
McGreivy JesseChief Medical OfficerAug 07Sale120.9234,0624,118,6100Aug 07 06:51 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMay 08Option Exercise25.947,710199,9979,653May 08 06:41 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingApr 29Option Exercise57.162,332133,2972,728May 01 06:14 PM